John T. Kilcoyne,Chief Executive Officer and President
John Kilcoyne brings more than 29 years of experience in the medical device market to RVO®. He has a proven record in understanding the needs of both patients and doctors, combined with an ability to move companies from development into the commercial market.
Most recently, he served as Chairman and CEO of Micrus Endovascular Corporation, until its sale to Johnson & Johnson in September 2010. Mr. Kilcoyne also served as President and Chief Executive Officer of Solace Therapeutics, a medical device company from 2002 to 2004. Prior to Solace, he served as the President and Chief Executive Officer of Endonetics, Inc. from 1997 until its acquisition by Medtronic in December 2001.
Mr. Kilcoyne received his B.S. from Cornell University.
Alain Schreiber, M.D.
Dr. Schreiber joined ProQuest as a General Partner in 2000. His extensive industry experience provides a commercially-focused operational discipline and a depth of drug development expertise. Prior to joining ProQuest, Dr. Schreiber served as President, Director, and CEO of Vical. Previously, at Rhône-Poulenc Rorer (now Sanofi), Dr. Schreiber served in several roles, including Senior Vice President of Research. Prior to his tenure at Rhône-Poulenc Rorer, Dr. Schreiber was Department Head of Biochemistry at Syntex (now Roche Bioscience). He has previously served on the Board of Directors of ActivX Biosciences, BioRexis Pharmaceutical Corp., Cabrellis Pharmaceuticals, Cadence Pharmaceuticals, Concentric Medical, Conforma Therapeutics, Excaliard Pharmaceuticals, Gemin X, LEAD Therapeutics, Optimer Pharmaceuticals and Somalogic. Currently, Dr. Schreiber serves on the Board of Directors of Aires Pharmaceuticals, Eagle Pharmaceuticals, Immune Design Corporation, Revision Optics, Telormedix and Tragara Pharmaceuticals.
Dr. Schreiber received a B.S. in chemistry, summa cum laude, and an M.D., summa cum laude, from the Free University in Brussels, Belgium. Subsequently, he was a postdoctoral fellow at the Weizmann Institute of Science in Israel.
Andy Corley co-founded eyeonics, Inc. in 1998. eyeonics developed and gained approval of a new category of intraocular lenses, the accommodating IOL. The company’s 5-year effort changed CMS policy to allow Medicare beneficiaries a choice in the selection of their intraocular lens associated with cataract surgery. eyeonics was sold to Bausch and Lomb in 2008 where Mr. Corley served as President of the Surgical Division. He was co-founder of Chiron Ophthalmics, where he was General Manager of the Refractive Surgery Division until 1997. In 2005 he was the Orange County Entrepreneur of the Year and the Crystalens was declared the AeA Technology of the Year.
In 2011 Mr. Corley formed Yelroc Consulting Inc. He is a graduate of Georgia Southern University.
Brian H. Dovey
Brian Dovey has been a Partner of Domain since 1988. Since joining Domain, he has served on the Board of Directors of over 35 private and public companies and has been Chairman of five. He is currently on the board of two public companies, Orexigen Therapeutics and REVA Medical.
Prior to Domain, Mr. Dovey spent six years at Rorer Group (now part of Sanofi-Aventis). As President of Rorer from 1986 to 1988, he was the primary architect of this company’s strategic shift to pharmaceuticals that resulted in a doubling of annual sales to approximately $1 billion. Mr. Dovey has served as both President and Chairman of the National Venture Capital Association. He was former Chair and currently serves on the Board of Directors of the Wistar Institute, a leader in preclinical bio-medical research in the non-profit sector.
Mr. Dovey serves on the Board of Directors and is also Chairman at the Center for Venture Education (Kauffman Fellows Program). He is a Trustee Emeritus of Germantown Academy, and is a former Trustee of the University of Pennsylvania School of Nursing and the Burnham Institute for Medical Research.
Mr. Dovey received his BA from Colgate University and a MBA from Harvard Business School.
Gilbert H. Kliman, MD
Gil joined InterWest’s healthcare team in 1996. He invests in a broad array of healthcare opportunities, focusing on medical devices and healthcare IT, with a special interest in ophthalmology. He is a board member of Autonomic Technologies, Benvenue, Doximity, Glaukos, Gobiquity, Restoration Robotics, and ReVision Optics.
Gil has led InterWest’s medical device team since 1999 and pioneered InterWest’s ophthalmology franchise. Prior to InterWest, Gil was a health care investor at TA Associates and at Norwest Venture Capital. A former practicing ophthalmologist and laser researcher, he was previously West Coast director of LCA Vision, and served as an assistant professor at Tufts New England Eye Center and on the clinical faculty at Massachusetts Eye and Ear Infirmary.
Gil has a B.A. from Harvard University. He received an M.D. from the University of Pennsylvania and an M.B.A. from Stanford University. He completed an ophthalmology residency at Wills Eye Institute and retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation Fellow. He also serves as a National Trustee for the Foundation Fighting Blindness.
Inna Martin Eitan
Inna Martin Eitan, Partner, RMI Partners, brings more than 15 years of experience in business development and fund raising for pharmaceutical and medical device projects in Israel. Prior to joining RMI, Inna served as a strategic business development and financial adviser to Israel’s leading healthcare focused VC firms and holding companies including Israel’s leading Venture firm Pontifax, selected projects from Maayan Ventures (TASE), Technion Stem Cell Foundation, Hadassit BioHoldings (TASE), and several private and government-backed technological incubators in Israel. In 2002-2004, Inna served as a Business Development Manager at a private biotech incubator EagerBio managed by Prof. Herzberg, the former Vice Chairman of the Pasteur Institute’s “Pasteur Enterprises” Bio-Top Incubator, Paris, France.
Currently, she serves on the boards of several privately held companies in the US and Israel.
Randy Alexander, Chairman of the Board
Randy Alexander is a leader in the ophthalmic industry. He has consistently created value and delivered growth, successfully launching four start-up companies.
He is the Chairman of ReVision Optics, Inc. and a seasoned senior executive and leader in the ophthalmic industry. Most recently, as CEO of IntraLase Inc., Mr. Alexander grew the business from a start-up to over $18 million in revenue in a little over four years.
Prior to IntraLase, Mr. Alexander was Senior Vice President of Chiron Vision, where he established Chiron Vision as a leader in the refractive surgery industry. At Chiron Vision, he created a $50 million refractive product line by identifying the LASIK surgical procedure, as well as acquiring patents and instrumentation. During his 28-year career in ophthalmology, Mr. Alexander has also served as CEO of Pharmacia Intermedics and Senior Vice President, Sales & Marketing of CILCO.
Mr. Alexander holds bachelor’s and master’s degrees in Biological Sciences from Marshall University.
Renee Compton Ryan, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation in 2011. She is based in Silicon Valley, California. Mrs. Ryan’s background includes over 20 years of healthcare investment banking. Most recently, she ran the medical device investment banking effort at R.W. Baird & Co. Previously, she lead the West Coast medical device group at Jefferies & Co. and was in the healthcare investment banking groups at Goldman Sachs and Credit Suisse. Mrs. Ryan received an MBA from Columbia Business School and a Bachelors degree from Georgetown University.
Stephen Slade, MD, FACS
Stephen Slade is an active researcher and the U.S. medical monitor for several new technologies, and has been a consultant on many FDA clinical trials. In addition to his position at Slade & Baker Vision Center of Houston, Tex., Dr. Slade is Chief Medical Editor of Cataract and Refractive Surgery Today. In 1991, Dr. Slade and Stephen Brint, M.D., performed the first LASIK procedure in the U.S. and later performed the first Custom LASIK ablation-based on topography in the U.S. He also was the first to perform and has the longest experience with all-laser LASIK, laser cataract surgery and the accommodating IOL for presbyopia.
Dr. Slade was elected president of the American-European Congress of Ophthalmic Surgery in January 2011 and is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons. He was named a Leading Ophthalmologist in America by Becker’s ASC Review and has received numerous awards, including 11 named lectures, Refractive Surgeon of the Year, two China Service Medals, the Summit Technologies Pioneer of Refractive Surgery Award, the Casebeer Award and the Lans Lectureship. In 2007 he received the Barraquer Award, the highest award from the largest society of refractive surgeons. Dr. Slade was selected by his peers for both “Best Doctors” and “Best Doctors in America,” and has received the Honor Award of the American Academy of Ophthalmology.
Healthcare investor Wende Hutton brings 20 years of experience to identifying, investing in and building companies that are changing the practice of medicine. She has facilitated bringing over a dozen medical devices and drugs to market, and currently sits on the boards of Aldea Pharmaceuticals, Butterfly Health, Chimerix (CMRX), Dermira, Labrys Biologics, ReVision Optics, Theraclone Sciences and Transcend Medical.
Wende joined Canaan in 2004, and her life sciences track record includes 6 IPOs and 4 acquisitions. She began her venture career at Mayfield Fund in 1993, where she worked closely with the founding teams of Heartstream (HPQ) and Northstar Neuroscience (NSTR). Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing.
Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is active with several community service groups including serving on the board of FACE AIDS.